Related Experiment Video

Updated: Sep 29, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.5K

PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives

Iwona Hus1, Bartosz Puła1, Tadeusz Robak2,3

  • 1Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.

Cancers
|March 25, 2022
PubMed

Insights

Phosphoinositide 3-kinase (PI3K) inhibitors target B-cell signaling in chronic lymphocytic leukemia (CLL). While effective, approved PI3K inhibitors like idelalisib and duvelisib have significant toxicities, prompting development of novel agents.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Phosphoinositide 3-kinases (PI3Ks) are crucial for cell growth, survival, and apoptosis, particularly class I PI3Ks in lymphocyte development and activation.
  • PI3Kδ isoform is predominantly expressed in B cells and its inhibition induces apoptosis in chronic lymphocytic leukemia (CLL) cells.
  • Selective PI3Kδ inhibitors have emerged as a therapeutic strategy for CLL, especially in high-risk patient populations.

Purpose of the Study:

  • To review the mechanism of action, efficacy, and toxicities of approved and investigational PI3K inhibitors (PI3KIs) for CLL treatment.
  • To highlight the clinical development of PI3KIs, including idelalisib, duvelisib, and umbralisib.
  • To discuss emerging PI3KIs in early-phase clinical trials for CLL.

Main Methods:

  • Literature review of PI3KIs in CLL treatment.
  • Analysis of clinical trial data for approved and investigational PI3KIs.
  • Summary of mechanisms of action, efficacy, and safety profiles.

Main Results:

  • Idelalisib, a PI3Kδ inhibitor, demonstrated efficacy in relapsed/refractory CLL but had notable side effects.
  • Duvelisib, a dual PI3Kδ/γ inhibitor, is approved for CLL but shares similar toxicities with idelalisib.
  • Umbralisib, targeting PI3Kδ and CK1ε, showed efficiency and safety in phase 3 CLL trials.

Conclusions:

  • PI3K inhibitors represent an important class of targeted therapies for CLL.
  • Balancing efficacy with manageable toxicity remains a key challenge in PI3KI development for CLL.
  • Ongoing research and novel PI3KIs hold promise for improved CLL management.
Keywords:
BGB-10188PI3-kinase inhibitorschronic lymphocytic leukemiacopanlisibduvelisibidelalisibparsaclisibsafetytreatmentumbralisibzandelisib

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

585

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
249
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
216